BioSpace News Archive

Deals

Aptorum Group Limited Announces Closing of Initial Public Offering

Aptorum Group Limited today announced the closing of its initial public offering (“IPO” or the “Offering”) of 761,419 Class A Ordinary Shares, at a public offering price of $15.80 per share.

December 17, 2018
·
6 min read
Biotech Beach

AVITA Medical Announces Receipt of A$1.4 Million Research and Development Tax Credit

AVITA Medical today announced that it has received a Research and Development Tax Incentive cash rebate from the Australian Tax Office in the amount of A$1,421,000 for the year ending 30 June 2018.

December 17, 2018
·
4 min read
FDA

Celltrion and Teva Snag Second Biosimilar Approval of a Genentech Drug

The U.S. Food and Drug Administration approved another biosimilar. On Friday, the regulatory agency approved Herzuma, a biosimilar to Genentech’s Herceptin developed by South Korea-based Celltrion, Inc. and Israel-based Teva Pharmaceuticals.

December 17, 2018
·
2 min read
·
Alex Keown
Business

Arrogance, Ambition and Sloppiness: More Details Behind the CRISPR Babies Story

In an in-depth investigation, STAT reported on behind-the-scenes activities at the Second International Summit on Human Genome Editing at the University of Hong Kong, where He made his announcement.

December 17, 2018
·
4 min read
·
Mark Terry
Deals

As GSK Bets on Tesaro’s Zejula, Clovis Stock Takes a Hit

Shares of Clovis Oncology fell more than 4 percent Friday after additional details surrounding GlaxoSmithKline’s $5.1 billion acquisition of Waltham, Mass.-based Tesaro Inc. was brought to life in a filing with the U.S. Securities and Exchange Commission.

December 17, 2018
·
2 min read
·
Alex Keown
Business

Seer Launches to Develop Protein-Based Liquid Biopsies

Yet another company has launched to develop liquid biopsies. Founded and headed by Omid Farokhzad, formerly a professor at Brigham and Women’s Hospital, Seer is based in San Francisco.

December 17, 2018
·
2 min read
·
Mark Terry
Business

Genentech Licenses Non-CF Compound From Proteostasis in $100 Million-Plus Deal

Proteostasis Therapeutics, based in Boston, signed a worldwide, exclusive license deal with Genentech for rights to a possible small molecule modulator within the proteostasis network.

December 17, 2018
·
2 min read
·
Mark Terry
Drug Development

Eli Lilly’s Taltz Stands up to Humira in Psoriatic Arthritis Patients

At 24 weeks, the study met its primary endpoint. Lilly’s Taltz demonstrated superiority against AbbVie’s Humira, the best-selling drug in the world, in improving the signs and symptoms of active PsA.

December 17, 2018
·
2 min read
·
Alex Keown
Drug Development

HIV Vaccine in Monkeys Suggests Human Vaccine on the Horizon

So far, a vaccine for HIV has been elusive. However, researchers with Scripps Research Institute recently published positive data about its HIV vaccine in the journal Immunity that suggests one might be on the horizon.

December 17, 2018
·
2 min read
·
Mark Terry
Policy

More Woes Continue for J&J and Its Iconic Talc Product as Report Details a History of Contamination

A Reuters analysis of company documents reveals that Johnson & Johnson knew about levels of asbestos contamination in its talc products, but did not report it to the FDA.

December 17, 2018
·
3 min read
·
Alex Keown